Open AccessRandomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia
Author(s) -
Henglin Yang,
Jingyan Wang,
Hui Liu,
Xingliang Li,
Ren-hua Nie,
Chunfu Li,
Hengye Wang,
Qinghu Wang,
Yaming Cao,
Liwang Cui
Publication year - 2018
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.00793-18
Subject(s) - medicine , azithromycin , malaria , malaria prophylaxis , randomized controlled trial , placebo , adverse effect , clinical trial , chemoprophylaxis , efficacy , drug , pharmacology , immunology , antibiotics , biology , alternative medicine , pathology , microbiology and biotechnology
New prophylactic drugs against malaria infections are urgently needed. We conducted randomized, double-blind, placebo-controlled, phase 2 trials of a new antimalarial drug combination, naphthoquine-azithromycin (NQAZ), to determine its safety and protective efficacy in a low-endemicity area of Southeast Asia.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom